You are here: Industry Insights > Pharma in China > Chinese-produced new drugs to be marketed soon in 2019

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Chinese-produced new drugs to be marketed soon in 2019

PharmaSources/CaicaiJanuary 21, 2019

Favorites

Chinese-produced new drugs to be marketed soon in 2019:

Pharmaceutical product name	Mechanism of action	Registration classification	Company
Polyethylene Glycol Loxenatide Injection	Long-acting GLP-1 receptor agonist	Chemical drug 1	Hansoh
Utidelone Injection	Non-taxane tubulin polymerization-resistant antitumor drug	Chemical drug 1	Biostar
Camrelizumab for Injection	Anti-PD-1 antibody	Biological product for treatment1	Jiangsu Suncadia
Avitinib Maleate Capsules	Third-generation EGFR TKI	Chemical drug 1	ACEA Pharma
Fumaritidine Mesylate Tablets	Second-generation Bcr-Abl TKI	Chemical drug 1	Hansoh
Zanubrutinib Capsules	BTK inhibitor	Chemical drug 1	BeiGene
Tislelizumab Injection	Anti-PD-1 antibody	Biological product for treatment 1	BeiGene, Celgene, Boehringer Ingelheim
Sodium Oligomannurarate Capsules	Marine oligosaccharide molecule	Chemical drug 1	Chinese Academy of Sciences and GreenValley

(Sorted out based on public data. Any supplementation will be much appreciated. *Jiangsu Suncadia is a subsidiary of Hengrui Medicine)

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Far-away from the CrowdMay 06, 2024

Ipsen Invested USD 900 Million to Introduce Sutro Biopharma ADC.

Spuer 203May 06, 2024

XiaobinMay 06, 2024

Krebs QinMay 06, 2024

Accelerated approval is a privilege that every applicant desires.